Outpatient parenteral antimicrobial therapy practices among adult infectious disease physicians
- PMID: 24915212
- PMCID: PMC4180108
- DOI: 10.1086/676859
Outpatient parenteral antimicrobial therapy practices among adult infectious disease physicians
Abstract
Objective: To identify current outpatient parenteral antibiotic therapy practice patterns and complications.
Methods: We administered an 11-question survey to adult infectious disease physicians participating in the Emerging Infections Network (EIN), a Centers for Disease Control and Prevention-sponsored sentinel event surveillance network in North America. The survey was distributed electronically or via facsimile in November and December 2012. Respondent demographic characteristics were obtained from EIN enrollment data.
Results: Overall, 555 (44.6%) of EIN members responded to the survey, with 450 (81%) indicating that they treated 1 or more patients with outpatient parenteral antimicrobial therapy (OPAT) during an average month. Infectious diseases consultation was reported to be required for a patient to be discharged with OPAT by 99 respondents (22%). Inpatient (282 [63%] of 449) and outpatient (232 [52%] of 449) infectious diseases physicians were frequently identified as being responsible for monitoring laboratory results. Only 26% (118 of 448) had dedicated OPAT teams at their clinical site. Few infectious diseases physicians have systems to track errors, adverse events, or "near misses" associated with OPAT (97 [22%] of 449). OPAT-associated complications were perceived to be rare. Among respondents, 80% reported line occlusion or clotting as the most common complication (occurring in 6% of patients or more), followed by nephrotoxicity and rash (each reported by 61%). Weekly laboratory monitoring of patients who received vancomycin was reported by 77% of respondents (343 of 445), whereas 19% of respondents (84 of 445) reported twice weekly laboratory monitoring for these patients.
Conclusions: Although use of OPAT is common, there is significant variation in practice patterns. More uniform OPAT practices may enhance patient safety.
Conflict of interest statement
Figures
Similar articles
-
Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey.Clin Infect Dis. 2006 Nov 15;43(10):1290-5. doi: 10.1086/508456. Epub 2006 Oct 10. Clin Infect Dis. 2006. PMID: 17051494
-
Perspectives of United States-based Infectious Diseases Physicians on Outpatient Parenteral Antimicrobial Therapy Practice.Open Forum Infect Dis. 2019 Oct 1;6(10):ofz363. doi: 10.1093/ofid/ofz363. Open Forum Infect Dis. 2019. PMID: 31429872 Free PMC article.
-
A national survey of infectious disease practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT).Infect Dis (Lond). 2015 Jan;47(1):39-45. doi: 10.3109/00365548.2014.967290. Epub 2014 Nov 21. Infect Dis (Lond). 2015. PMID: 25415655
-
Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement.J Antimicrob Chemother. 2012 May;67(5):1053-62. doi: 10.1093/jac/dks003. Epub 2012 Jan 31. J Antimicrob Chemother. 2012. PMID: 22298347 Review.
-
Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?Infection. 2019 Apr;47(2):169-181. doi: 10.1007/s15010-018-1250-1. Epub 2018 Nov 15. Infection. 2019. PMID: 30443780 Review.
Cited by
-
Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study.BMC Pharmacol Toxicol. 2018 Aug 6;19(1):50. doi: 10.1186/s40360-018-0240-3. BMC Pharmacol Toxicol. 2018. PMID: 30081959 Free PMC article.
-
Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy.Clin Infect Dis. 2018 Jan 6;66(1):11-19. doi: 10.1093/cid/cix733. Clin Infect Dis. 2018. PMID: 29020202 Free PMC article.
-
The Impact of a Standardized Discharge Process on 30-Day Readmissions for Patients on Outpatient Parenteral Antibiotic Treatment.Hosp Pharm. 2022 Feb;57(1):107-111. doi: 10.1177/0018578720985434. Epub 2020 Dec 29. Hosp Pharm. 2022. PMID: 35521026 Free PMC article.
-
Risk Factors Associated With Nephrotoxicity During Outpatient Intravenous Vancomycin Administration.J Pharm Technol. 2022 Feb;38(1):10-17. doi: 10.1177/87551225211054378. Epub 2021 Nov 18. J Pharm Technol. 2022. PMID: 35141722 Free PMC article.
-
Diffusion of Newer HIV Prevention Innovations: Variable Practices of Frontline Infectious Diseases Physicians.Clin Infect Dis. 2016 Jan 1;62(1):99-105. doi: 10.1093/cid/civ736. Epub 2015 Sep 18. Clin Infect Dis. 2016. PMID: 26385993 Free PMC article.
References
-
- Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. The Medical journal of Australia. 1998;169(10):519–522. - PubMed
-
- Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy. 2001;47(Suppl 1):17–23. - PubMed
-
- Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings. Am J Surg. 1984;148(4A):1–4. - PubMed
-
- Tice AD. Outpatient parenteral antimicrobial therapy for osteomyelitis. Infect Dis Clin North Am. 1998;12(4):903–919. - PubMed
-
- Esposito S, Noviello S, Leone S, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents. 2004;24(5):473–478. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- L30 AR063363/AR/NIAMS NIH HHS/United States
- K12 HD001459/HD/NICHD NIH HHS/United States
- U54 CK000162/CK/NCEZID CDC HHS/United States
- KL2 RR024994/RR/NCRR NIH HHS/United States
- KM1CA156708/CA/NCI NIH HHS/United States
- KM1 CA156708/CA/NCI NIH HHS/United States
- KL2 TR000136/TR/NCATS NIH HHS/United States
- UL1RR024992/RR/NCRR NIH HHS/United States
- UL1 RR024992/RR/NCRR NIH HHS/United States
- KL2RR024994/RR/NCRR NIH HHS/United States
- 1U50CK000187/CK/NCEZID CDC HHS/United States
- CU54 CK 000162/CK/NCEZID CDC HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- 5K12HD001459-13/HD/NICHD NIH HHS/United States
- U50 CK000187/CK/NCEZID CDC HHS/United States
- KL2 TR000450/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical